Capricor Therapeutics Faces Class Action with Investors Watching Closely

Overview of Capricor Therapeutics and Recent Developments

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotech company focused on innovative therapies for muscular dystrophies, has recently found itself in the spotlight due to significant legal challenges. On August 20, 2026, the national investor rights law firm Hagens Berman brought attention to a class action lawsuit against Capricor, following troubling financial disclosures from the company that raised alarms for investors.

During the company's Q2 2026 earnings release, Capricor reported a staggering net loss of $40.7 million along with a cash reserve of $237.9 million. However, this financial update was marred by the absence of a live Q&A session with analysts, a decision attributed to ongoing discussions with the FDA regarding their regulatory path. This omission and the broader context of the company's financial health fueled uncertainties among investors about the integrity of the company’s trial data and overall management strategies.

Class Action Lawsuit Details

The class action lawsuit is particularly significant as it revolves around potential securities fraud linked to misleading statements made by Capricor's executives. Investors who suffered financial losses due to the recent disclosures are encouraged to submit their claims ahead of the lead plaintiff deadline set for September 28, 2026.

Key Allegations Against Capricor

1. Misleading Clinical Data: The lawsuit cites material false statements regarding clinical trial data and regulatory pathways for Capricor's leading product candidate, Deramiocel, intended for treating Duchenne muscular dystrophy (DMD). It alleges that changes to the pre-specified Statistical Analysis Plan (SAP) were made without proper FDA agreement.

2. The Impact of the HOPE-3 Trial: On December 3, 2025, Capricor's announcement of "Positive Topline Results from the Pivotal Phase 3 HOPE-3 Study of Deramiocel" initially buoyed investor confidence, leading to a 370% surge in share price. However, subsequent revelations of unapproved SAP modifications resulted in a dramatic 64% stock collapse after the FDA's advisory committee voted against the drug's efficacy on July 27, 2026.

What Should Affected Investors Do?

Investors who purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026, and experienced significant financial losses, are advised to act before the lead plaintiff deadline. They need not pursue lead plaintiff status to participate in any potential recovery from the ongoing litigation.

Hagens Berman’s Commitment

Hagens Berman, the law firm at the forefront of this lawsuit, has committed to investigating the full scope of the allegations, with a focus on holding corporate management accountable for their actions. Reed Kathrein, a partner at the firm, emphasized the importance of transparency and the protection of investor interests.

Conclusion

Capricor Therapeutics stands at a critical juncture as it navigates the legal ramifications of this class action lawsuit. Investors are urged to stay informed and consider their legal options as the deadline approaches. For more information or to report potential claims, affected investors can contact Hagens Berman directly.

In summary, as Capricor faces this uphill battle, the implications for investors could be significant, making it essential for them to remain vigilant in this ever-evolving situation.